Tirzepatide, a novel ‘twincretin’ targeting both GLP-1 and GIP receptors, has demonstrated efficacy for treating T2DM in the SURPASS clinical trial program [168] and overweight/obesity in the SURMOUNT studies [169]. Here, GLP1R is linked to Obesity.